申请人:Regen BioPharma, Inc.
公开号:US20180214413A1
公开(公告)日:2018-08-02
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
目前的技术是针对核受体活性调节剂,具体是针对NR2F6活性的调节和利用NR2F6化合物的调节,以及通过将本文描述的化合物用于人体来进行免疫调节和调节癌症干细胞活性。